Baseline vitamin D deficiency occurred in 73.08% of TAO patients receiving IVGC therapy with calcium supplementation.
This retrospective cohort study included 52 patients with thyroid-associated ophthalmopathy who completed intravenous glucocorticoid (IVGC) therapy with standardized vitamin D and calcium supplementation at the First Affiliated Hospital of Xi'an Jiaotong University. The study assessed treatment response to IVGC alongside baseline biomarkers including triglycerides, thyroxine, duration of ophthalmopathy, beta-CTX, N-MID OC, and 25(OH)D levels.
Analysis revealed that baseline triglycerides and thyroxine levels were significantly higher in non-responders compared to responders. Additionally, the duration of ophthalmopathy was longer in non-responders. Conversely, baseline beta-CTX and N-MID OC levels were higher in responders. Baseline 25(OH)D deficiency was present in 73.08% of the patients.
Safety and tolerability data were not reported, as were discontinuations and serious adverse events. The study notes that the relationship between vitamin D and IVGC efficacy remains undefined. Because this is an observational study, causal inferences cannot be made regarding the impact of vitamin D supplementation or baseline biomarkers on treatment outcomes.